FDA Approves New Antibiotic for Three Different Uses

The U.S. Food and Drug Administration has approved Zevtera for treating adults with Staphylococcus aureus bloodstream infections (SAB), acute bacterial skin and skin structure infections (ABSSSI), and community-acquired bacterial pneumonia (CABP). The FDA is committed to promoting new antibiotic availability when they prove safe and effective. Zevtera’s efficacy was evaluated in a randomized, controlled, double-blind, multinational, multicenter trial, with 69.8% of subjects achieving overall success compared to 68.7% of subjects receiving the comparator.